Evidence map›Paper›PMID 39890534›Full record

ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2025

Perivascular brain clearance as a therapeutic target in cerebral amyloid angiopathy and Alzheimer's disease.

Orla Bonnar, Beth Eyre, Susanne J van Veluw

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Engulfment by brain macrophages in a short-lived vertebrate.bioRxiv : the preprint server for biology · 2026
    Article
  5. Toxic mechanisms of amyloid oligomers and therapeutic strategies.Protein science : a publication of the Protein Society · 2026
    Review
  6. Review
  7. Review
  8. Meningeal lymphatic dysfunction drives cognitive impairment after experimental subarachnoid hemorrhage.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Article
  9. Review
  10. Article
  11. Review
  12. Emerging approaches to bridging discovery science with clinical care in Alzheimer's disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Orla BonnarMassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA. Electronic address: obonnar@mgh.harvard.edu.
Beth EyreMassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
Susanne J van VeluwMassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA; J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Funding

Mechanisms of Vasomotion-mediated Perivascular Clearance in Cerebral Amyloid AngiopathyR01NS128790 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI Steven M Greenberg · 2022 to 2026
$2.9M
American Heart Association-American Stroke Association 24POST1187589NINDS NIH HHS R01 NS128790
6 · The paper itself

Abstract

Although distinct diseases, both cerebral amyloid angiopathy (CAA) and Alzheimer's disease (AD) are characterized by the aggregation and accumulation of amyloid-β (Aβ). This is thought to be due, in part, to impaired perivascular Aβ clearance from the brain. This shared failure in both diseases presents a common opportunity for therapeutic intervention. In this review we discuss the idea that promoting perivascular brain clearance could be an effective strategy for safely reducing Aβ levels in CAA and AD thereby improving clinical outcomes, most notably hemorrhagic stroke and cognitive decline. We will explore the evidence for the different forces that are thought to drive perivascular brain clearance, review the literature on potential strategies for potentiating these driving forces, and finally we will discuss the substantial translational challenges and considerations that would accompany such an intervention.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBrainCerebral Amyloid AngiopathyGlymphatic SystemAnimalsHumansAmyloid beta-PeptidesCerebral amyloid angiopathyGlymphatic systemIntramural periarterial drainageMixingVascular smooth muscle cells

Identifiers

PMID39890534
PMCPMC12047398

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.